HarbourVest Partners LLC maintained its position in Atara Biotherapeutics Inc (NASDAQ:ATRA) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,543 shares of the biotechnology company’s stock at the end of the first quarter. Atara Biotherapeutics accounts for about 0.1% of HarbourVest Partners LLC’s holdings, making the stock its 18th largest position. HarbourVest Partners LLC’s holdings in Atara Biotherapeutics were worth $217,000 at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. Norges Bank acquired a new position in Atara Biotherapeutics during the fourth quarter valued at approximately $4,031,000. Artal Group S.A. increased its position in Atara Biotherapeutics by 122.2% in the fourth quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock valued at $7,100,000 after buying an additional 275,000 shares during the last quarter. State Street Corp increased its position in Atara Biotherapeutics by 62.8% in the fourth quarter. State Street Corp now owns 600,521 shares of the biotechnology company’s stock valued at $8,526,000 after buying an additional 231,541 shares during the last quarter. EcoR1 Capital LLC increased its position in Atara Biotherapeutics by 101.5% in the first quarter. EcoR1 Capital LLC now owns 434,812 shares of the biotechnology company’s stock valued at $8,935,000 after buying an additional 219,000 shares during the last quarter. Finally, Eagle Asset Management Inc. increased its position in Atara Biotherapeutics by 14.1% in the first quarter. Eagle Asset Management Inc. now owns 1,267,609 shares of the biotechnology company’s stock valued at $26,049,000 after buying an additional 156,911 shares during the last quarter. 81.50% of the stock is currently owned by hedge funds and other institutional investors.
Atara Biotherapeutics Inc (ATRA) traded up 0.37% during trading on Tuesday, reaching $13.50. 242,367 shares of the company’s stock traded hands. The firm’s market cap is $392.97 million. The firm has a 50 day moving average price of $14.32 and a 200-day moving average price of $16.15. Atara Biotherapeutics Inc has a 12 month low of $11.80 and a 12 month high of $25.73.
COPYRIGHT VIOLATION WARNING: This news story was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://sportsperspectives.com/2017/06/20/harbourvest-partners-llc-has-217000-stake-in-atara-biotherapeutics-inc-atra.html.
Several equities analysts have commented on ATRA shares. Canaccord Genuity reissued a “buy” rating and set a $47.00 target price on shares of Atara Biotherapeutics in a research report on Friday, April 21st. Citigroup Inc. set a $10.00 target price on shares of Atara Biotherapeutics and gave the stock a “sell” rating in a research report on Thursday, March 16th. Finally, Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. Three equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $24.00.
In related news, CEO Isaac E. Ciechanover sold 16,000 shares of the company’s stock in a transaction dated Tuesday, March 28th. The shares were sold at an average price of $20.06, for a total value of $320,960.00. Following the transaction, the chief executive officer now owns 725,951 shares in the company, valued at approximately $14,562,577.06. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO John Mcgrath sold 14,000 shares of the company’s stock in a transaction dated Thursday, March 23rd. The shares were sold at an average price of $20.65, for a total transaction of $289,100.00. Following the completion of the transaction, the chief financial officer now owns 119,327 shares in the company, valued at approximately $2,464,102.55. The disclosure for this sale can be found here. In the last quarter, insiders sold 94,008 shares of company stock worth $1,594,911. 16.10% of the stock is owned by company insiders.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.